Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera (NASDAQ: NTRA) has reached a significant milestone in its EXPAND clinical trial, with enrollment exceeding 1,600 patients. The trial evaluates Fetal Focus™, a single gene noninvasive prenatal test (NIPT) for inherited conditions.
Initial results from EXPAND demonstrated 91% sensitivity, successfully identifying all 5 cases of homozygous variants. The trial, initiated in 2023, is distinguished by its comprehensive validation approach, confirming both positive and negative results through diagnostic testing.
Fetal Focus™ serves as an alternative testing option when biological fathers are unavailable for carrier testing, though testing both partners remains the gold standard. Natera expects to report comprehensive trial analysis in Q4 2025.
Natera (NASDAQ: NTRA) has published a groundbreaking study in the Journal of Clinical Oncology - Precision Oncology validating its Signatera™ test for testicular cancer. The multi-institutional study, analyzing 324 plasma samples from 74 patients, demonstrated that Signatera significantly outperformed standard serum tumor markers (STM) in predicting patient outcomes.
The study revealed impressive detection rates with Signatera showing 91.6% positivity for stage I and 100% for stages II and III. Notably, Signatera-positive patients showed significantly shorter event-free survival compared to Signatera-negative patients, with a hazard ratio of 12.45 (p0.0001) during surveillance, while conventional STMs failed to show significant correlation with outcomes.
Natera (NASDAQ: NTRA) has published a new study in the Journal of Clinical Oncology Precision Oncology validating its Signatera™ test for monitoring uterine cancer recurrence. The multi-center study analyzed 233 plasma samples from 61 patients with stage I/II uterine cancer.
The study demonstrated that Signatera achieved 100% detection of cancer recurrences before clinical confirmation, with a median lead time of 3.1 months. The test proved highly prognostic in both postoperative (HR=7.6) and post-definitive therapy (HR=25.4) settings, outperforming traditional risk assessment methods. Notably, no patients who tested consistently negative with Signatera experienced recurrence.
Natera (NASDAQ: NTRA) provided an update on its patent litigation with NeoGenomics. The U.S. District Court for the Middle District of North Carolina invalidated certain claims in two patents related to NeoGenomics' v1.1 RaDaR test. However, this ruling does not affect U.S. Patent No. 11,519,035, which previously secured both preliminary and permanent injunctions against NeoGenomics' RaDaR v1.0 product.
The company is considering its options, including an appeal and enforcement of other patents. Natera emphasizes its strong intellectual property position with over 500 issued or pending patents worldwide and remains committed to protecting its innovation investments.
Natera (NASDAQ: NTRA) has announced the activation of the ARCHER (NRG-GU015) trial, a pivotal Phase III study in muscle-invasive bladder cancer (MIBC). The study will evaluate whether a shorter radiation course can match current standard-of-care outcomes, incorporating Natera's Signatera™ personalized molecular residual disease (MRD) test as a secondary endpoint.
The trial, sponsored by NRG Oncology through the National Cancer Institute, will involve over 100 sites across the U.S. and Canada. Signatera will monitor circulating tumor DNA (ctDNA) clearance patterns to predict treatment response and recurrence, with additional exploration of urine tumor DNA. The test has been clinically validated to detect MIBC recurrence earlier than standard imaging.
This initiative builds on Natera's existing MIBC clinical evidence, including positive results from the IMVigor011 trial, which demonstrated Signatera's effectiveness in predicting immunotherapy benefits post-cystectomy.
Natera (NASDAQ: NTRA) announced upcoming presentations at the 2025 International Association for the Study of Lung Cancer (IASLC) World Conference in Barcelona, Spain from September 6-9. The company will showcase new data demonstrating the clinical utility of its Signatera™ technology in lung cancer patients.
A key highlight includes an oral presentation featuring analysis of Signatera Genome in early-stage, resectable non-small cell lung cancer (NSCLC) patients, showing its prognostic value for recurrence-free and overall survival in post-surgical molecular residual disease assessment. Three presentations will cover various aspects of Signatera's application in lung cancer monitoring and treatment outcomes.
Natera (NASDAQ: NTRA), a leader in cell-free DNA testing and precision medicine, has achieved a significant milestone with over 300 peer-reviewed publications featuring its technology. The publications span prestigious journals including Nature, Nature Medicine, and others, demonstrating the company's scientific leadership.
The milestone encompasses 150+ oncology publications (140+ focused on Signatera™), 100+ publications on Women's Health technologies, and 60+ publications on Organ Health solutions. These studies validate Natera's contributions to disease detection and clinical decision-making across multiple medical disciplines.
Natera (NASDAQ: NTRA) has launched its proprietary AI foundation model platform aimed at advancing diagnostic and therapeutic innovation in precision medicine. The platform is built on one of the largest multimodal oncology datasets, including over 250,000 tumor exomes and 1 million+ plasma timepoints.
The platform consists of three integrated layers: a data foundation layer with extensive oncology datasets, a core model layer powered by over 1 billion parameters, and an application layer featuring tools like the Digital Patient Simulator, Real-Time Trial Matching, and NeoPredict. Initial pilot programs have demonstrated strong performance in recommending immunotherapy and predicting treatment responses.
Natera (NASDAQ: NTRA) has announced positive topline results from the Phase III IMvigor011 trial in muscle-invasive bladder cancer (MIBC), utilizing their Signatera ctDNA test. The trial demonstrated that Signatera-positive patients treated with atezolizumab showed significant improvements in disease-free survival and overall survival.
The study enrolled approximately 760 patients who underwent Signatera testing post-surgery. Notably, patients who remained Signatera-negative showed exceptional outcomes, with 100% overall survival at 12 months and 98% at 18 months. Disease-free survival rates were 92% at 12 months and 88% at 18 months after surgery.
Following these results, Natera will finalize its premarket approval application to the FDA for Signatera as a companion diagnostic for atezolizumab treatment selection in MIBC patients post-cystectomy.
Natera (NASDAQ: NTRA) reported strong Q2 2025 financial results with total revenues of $546.6 million, up 32.2% year-over-year. The company achieved significant milestones including a gross margin of 63.4% and processed 853,100 tests, a 12.2% increase from Q2 2024.
Notable highlights include 50.6% growth in oncology tests to 188,800 units and positive cash flow of $24.3 million. The company raised its 2025 revenue guidance to $2.02-$2.10 billion, an $80 million increase at the midpoint. However, Natera reported a net loss of $100.9 million ($0.74 per share), impacted by legal accruals and stock-based compensation expenses.